Inhibitec is a biotech company with the mission to develop a novel therapeutic approach for the treatment of inflammatory chronic and autoimmune diseases. Inhibitec is a startup company with its foundation on the Spanish National Research Council (CSIC) and the University of Cantabria (UC). Our main goal is to position B101.37, a specific monoclonal antibody targeting BAMBI (BMP and Activin Membrane-Bound Inhibitor), as a new standard in the treatment of psoriasis and psoriatic arthritis (PsA).